These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12211161)

  • 21. Simplifying suppression: switching therapies to improve HIV disease management.
    Moyle GJ
    AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867
    [No Abstract]   [Full Text] [Related]  

  • 22. Damage to the power plant.
    TreatmentUpdate; 2002 Mar; 14(3):1-2. PubMed ID: 12033185
    [No Abstract]   [Full Text] [Related]  

  • 23. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.
    Kosmiski LA; Miller HL; Klemm DJ
    Antivir Ther; 2006; 11(2):187-95. PubMed ID: 16640100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A chat with HIV specialists: the Geneva report.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():12-7. PubMed ID: 11367483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 26. [Changes in lipid metabolism of patients infected by human immunodeficiency virus. A pathogenic hypothesis].
    Rodríguez Vidigal FF; Muñoz Sanz A
    Med Clin (Barc); 2000 Jun; 115(4):145-50. PubMed ID: 10996887
    [No Abstract]   [Full Text] [Related]  

  • 27. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 28. Face to face with lipoatrophy. An interview with David Nolan by Nelson Vergel.
    Nolan D
    GMHC Treat Issues; 2005; 19(3-4):1-6. PubMed ID: 16003843
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of once-daily antiretroviral therapy.
    Boyle BA
    AIDS Read; 2002 Mar; 12(3):90-2, 95-6, 109. PubMed ID: 11966243
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 31. Longitudinal studies of the role of NRTIs in fat loss.
    Currier J
    AIDS Clin Care; 2002 Dec; 14(12):106-7. PubMed ID: 12510657
    [No Abstract]   [Full Text] [Related]  

  • 32. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.
    Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P
    HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double jeopardy: the hazards of drug-drug interactions.
    Flexner C
    Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cohort studies: what do they tell us?
    Chêne G
    J HIV Ther; 2001 May; 6(2):28-31. PubMed ID: 11501200
    [No Abstract]   [Full Text] [Related]  

  • 35. Current HIV therapeutics: mechanistic and chemical determinants of toxicity.
    Chiao SK; Romero DL; Johnson DE
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):53-60. PubMed ID: 19152213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

  • 37. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 38. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.
    Mallon PW
    AIDS Rev; 2007; 9(1):3-15. PubMed ID: 17474309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ever-changing HIV treatment landscape.
    Berger DS
    Posit Aware; 2003; 14(1):69-70, 76. PubMed ID: 12630378
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiretroviral drugs and the risk of myocardial infarction.
    Zangerle R; Sarcletti M
    N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.